Neurology—Healthy Aging, Measured Early.
Neurology is entering a new era: the future will be defined not by late-stage diagnosis, but by early detection, longitudinal monitoring, and prevention-driven care. Alzheimer’s disease and Parkinson’s disease begin developing years — often decades — before symptoms become obvious, and by the time cognition or motor function declines, the biological window for intervention is already narrowing.
We are building neurology tests designed for healthy aging and early disease interception. Our approach leverages ultra-sensitive, clinically disciplined molecular measurement to detect subtle, disease-relevant signals at the earliest possible stage. Rather than relying on single-marker snapshots, our neurology programs are designed to integrate functional molecular signatures that better reflect real biological state and progression risk. This is not research for curiosity. This is diagnostics engineered for real-world clinical action.
Why Sensitivity Matters in Neurology
In neurodegeneration, the hardest signal to measure is the one that matters most — early, low-abundance molecular change. The difference between late detection and early interception is sensitivity, stability, and reproducibility across time. Our neurology testing philosophy is built around capturing weak signals reliably, tracking them longitudinally, and turning that information into clinically interpretable insight for patients and physicians. Healthy aging is not a slogan. It is a measurable biological trajectory.
Expertise-Driven, Built for Translation
Our neurology testing programs are developed with translational rigor and clinical feasibility from day one. We bring deep expertise in sensitive molecular detection, quantitative discipline, and cohort-scale analytics to neurology applications where false negatives and ambiguous results have real consequences.
The objective is clear: enable earlier screening, better stratification, and more actionable monitoring — so patients and clinicians can make decisions before disease becomes irreversible. We are building the measurement layer for healthy aging and early neurodegenerative screening.
✓ Ultra-sensitive molecular detection engineered for early-stage signals
✓ Quantitative stability suitable for longitudinal tracking
✓ Clinically structured outputs designed for real-world use